Research Article

Medication adherence and its impact on glycemic control in type 2 diabetes mellitus patients with comorbidity: A multicenter cross-sectional study in Northwest Ethiopia

Ashenafi Kibret Sendekie1*, Adeladlew Kassie Netere1, Asmamaw Emagn Kasahun2, Eyayaw Ashete Belachew2

1 Department of Clinical Pharmacy, School of Pharmacy, College of Medicine and Health Science, University of Gondar, Gondar, Ethiopia, 2 Department of Pharmaceutics, School of Pharmacy, College of Medicine and Health Science, University of Gondar, Gondar, Ethiopia

* ashukib02@yahoo.com, Ashenafi.Kibret@uog.edu.et

Abstract

Background

Medication nonadherence in patients with chronic diseases, particularly in type 2 diabetes mellitus (T2DM) with comorbidity, has continued to be the cause of treatment failure. The current study assessed medication adherence and its impact on glycemic control in T2DM patients with comorbidity.

Methods

An institutional-based multicenter cross-sectional study was conducted among T2DM patients with comorbidity at the selected hospitals in Northwest Ethiopia. Medication adherence was measured using a structured questionnaire of the General Medication Adherence Scale (GMAS). A logistic regression model was used to identify predictors of the level of medication adherence and glycemic control. P < 0.05 at 95% confidence interval (CI) was statistically significant.

Results

A total of 403 samples were included in the final study. This study showed that more than three-fourths (76.9%) of the participants were under a low level of medication adherence. Source of medication cost coverage [AOR = 10.593, 95% CI (2.628–41.835; P = 0.003], monthly income (P < 0.00), self-monitoring of blood glucose (SMBG) practice [AOR = 0.266, 95% CI (0.117–0.604); P = 0.002], number of medications [AOR = 0.068, 95% CI (0.004–0.813); P = 0.014] and medical conditions [AOR = 0.307, 95% CI (0.026–0.437); P = 0.018] were found to be significant predictors of medication adherence. Significantly, majority (74.7%) of participants had poor levels of glycemic control. Patients who had a high level of medication adherence [AOR = 0.003, 95% CI (0.000–0.113); P = 0.002] were found less likely to have poor glycemic control compared with patients who were low adherent to their medications.
Conclusion

The current study concluded that medication adherence was low and significantly associated with poor glycemic control. Number of medical conditions and medications were found to be associated with medication adherence. Management interventions of T2DM patients with comorbidity should focus on the improvement of medication adherence.

Introduction

Diabetes mellitus (DM) continues to be a public health problem worldwide with the number of people presenting with diabetes estimated to be 783 million by 2045 [1]. The prevalence of T2DM in developing countries has increased rapidly worldwide and accounts for more than 95% of diabetes cases [2]. The majority (three-fourths) of the diabetes patients are living in low and middle-income countries [3]. In Africa, it was reported to be 24 million in 2021 and estimated to reach 55 million (5%) by 2045 [1]. This makes diabetes becomes among the most common public health threats. The growth rate of DM has also increased in Ethiopia, and there is an observable change in lifestyle and significant increases in population and urbanization, which are the identified risk factors for DM. About more than two and a half million adults in Ethiopia have currently live with diabetes [4], and the prevalence has increased dramatically from 3.8% to 5.2% [5]. These make Ethiopia as one of the sub-Saharan Africa countries with the largest population of diabetes. While T2DM is estimated to be higher than this figure and the pooled prevalence reaches 8% [6].

The main treatment goal of diabetes patients is to maintain glycemic control and prevent diabetes-related complications, and morbidities and mortality [7]. However, suboptimal management of patients leads to treatment failure and complications [8]. For treating patients with diabetes, self-monitoring of blood glucose (SMBG), lifestyle modifications and the administration of medications are the recommended management interventions [9]. Nevertheless, medication non-adherence to the prescribed regimens has been continued to be a barrier of effective treatment outcome in the management of chronic disease conditions [7, 10]. Non-adherence to prescribed medication regimes contributes to treatment failure, risk of hospitalization, and morbidity and mortality in patients with long-term medication therapy [11].

Globally, a significant proportion of T2DM patients are non-adherent to their prescribed medications. Even, in the developed states around 50% of patients are non-adherent to their long-term medication and it is also much higher in low-and middle-income countries [12]. Personal and socio-demographic characteristics as well as medication regimen complexity, clinical characteristics and the number of medical conditions are factors that influence medication adherence in patients with chronic diseases [13–17]. Different studies have shown that non-adherence to prescribed medications in patients with diabetes mellitus is reported to be high and ranges from 6.3% to 87% [7, 18–20]. Evidence suggests that non-adherence to diabetes medications affects glycemic control that leads to complications associated with diabetes progression, hospitalizations, morbidity and mortality [3, 17, 21–24]. This in turn increases the risk of negative consequences and high medical costs with considerable direct and indirect problems to the sustainability of the healthcare system [3, 17, 21–24].

Studies also revealed that knowledge about diabetes and medications, level of patient educational status, occupational status, duration of diabetes and its treatments are among the factors that contribute to medication adherence [25–28]. Majority of patients with T2DM in Ethiopia are with comorbidities such as hypertension, dyslipidemia and macrovascular complications and had significantly poor glycemic control [28, 29]. Polypharmacy and medication regimen
complexity have been considered to be the most factors of poor adherence to medications among patients with chronic disease conditions and comorbidities [30, 31]. The burden of diabetes has increased and the prevalence of comorbidities is much higher among T2DM patients in Ethiopia. However, there is a paucity of real-world evidence, particularly in the study settings, which assessed medication adherence and its impact on glycemic control among T2DM patients with comorbidities. Therefore, this study assessed medication adherence among patients with T2DM and comorbidity at selected hospitals in Northwest Ethiopia. Moreover, the study also assessed the impact of medication adherence on glycemic control in patients with T2DM.

Methods and materials

Study design, settings and participants

An institutional-based multicenter cross-sectional study was conducted among T2DM patients with comorbidity. The study was employed in outpatient follow-up clinics at selected hospitals in Northwest Ethiopia from January to March 2022. The study area Northwest Ethiopia is the geographical location of the Northwestern part of the Amhara regional state, which is a metropolitan area and one of the Ethiopian government administration regional states. The study samples were recruited from the University of Gondar Comprehensive specialized hospital (UoGCSH), Tibebe-Ghion Comprehensive Specialized hospital (TGCSH), Felege-Hiwot Comprehensive Specialized hospital (FHCSH) and Debre-Tabor Comprehensive Specialized hospital (DTCH). The study hospitals are governmental hospitals, which have been served more than 20 million population and were randomly selected among several public and university hospitals found in the region. All the selected hospitals have chronic follow-up clinics, including diabetes patient care.

To be included in the study, participants should be adults (aged 18 years or older), diagnosed with T2DM, and are diagnosed with at least one comorbidity. In addition, they have been on treatment for at least a minimum of three months. While patients who were unable to communicate because of neurological or psychiatric illness, and/or severely ill patients, pregnant mothers, patients with incomplete medical records were excluded from this study.

Sample size determination and sampling techniques

We determined the sample size using a single population proportion formula by considering; response distribution, $P = 0.5$ (50%), and at 95% confidence interval, the marginal error was 5% for the two-tailed type-1 error ($Z_{\alpha} = 1.96$). The sample size was to be 385. Finally, considering a 10% potential nonresponse to the interview and/or missed or lost data on the patient’s medical record, 423 patients were approached in the final study. Then, the final sample size was proportionally divided into the selected hospitals to take a representative sample from each hospital. The number of patients with T2DM in each hospital was taken from records of the previous three follow-up months in the settings. All T2DM patients who fulfilled the inclusion criteria and come for follow-up during the data collection periods were approached until the required sample was achieved. Eventually, proportional to the number of T2DM patients in the selected hospitals; 174, 125, 68, and 56 eligible patients were included at the diabetes follow-up clinics of UoGCSH, FHCSH, DTCSH and TGCSH hospitals, respectively. Study participants from all selected hospitals were included using consecutive sampling technique.

Data collection instruments and procedures

Data was collected using a structured questionnaire. The data collection tool was prepared in English version after reviewing different related literature on similar topics and some
modified were made considering the local clinical settings. It was translated to local language, Amharic for making easy for data collection process. The tool was organized with different sections. The first section consisted of socio-demographic sections that included age, sex, weight, BMI, residency, educational status, employment status, physical activity, SMBG practice and cigarette smoking habit of the participants. The second section describes the clinical characteristics of the participants. This section is consisted of a type of medical condition such as comorbidities and complications, number of medical conditions, laboratory tests, blood glucose and blood pressure values and prescribed medications used for treating the study participants. Questionnaires assessing medication adherence is the last section of the data collection instrument.

The data was collected by four experienced nurses and two pharmacists from the hospitals after getting of training on the purpose of the study, data collection instruments and producers and about ethical aspects. The data collectors were engaged voluntarily. After the medical record identification numbers were entered into the Microsoft excel 2013 and checked for repetition, the data were extracted, and the patients were interviewed. Data were collected on direct patient interviews for primary data, and laboratory tests, medical conditions and dosage of medications were recorded from patients’ medical records. Laboratory test results were also checked from printed laboratory records.

Treatment intensification and titrations were made according to ADA recommendations. Metformin alone or with insulin and/or glibenclamide were the medication regimens used to treat T2DM in the study settings. The glycemic level of the participants was determined by an average of three different records of FBG, at least one month apart, this was because of inconsistent records of HbA1c in the study settings and included participants. In the resource-limited settings, a very limited number of patients were monitored using HbA1c in a regular fashion. The weight and height of the participants were measured using a digital weight scale and stadiometer as physical examination part.

Adherence
It indicates the active, voluntary, and collaborative decisional involvement of the patient in a mutually acceptable course of behavior to produce a therapeutic result.

Body mass index (BMI)
It is measured from weight in kilograms (kg) divided by the square of the patient’s height in meters (kg/m2). Based on the world health organization; BMI was classified and interpreted as $\leq$ 18.5 kg/m2 (underweight), 18.5–24.9 kg/m2 (normal weight), 25–29.5 kg/m2 (overweight) and $\geq$ 30 kg/m2 (obesity).

Outcome measurements

Adherence measurement
Medication adherence was measured by using the General Medication Adherence Scale (GMAS), which has an 11-item questionnaire that provides a convenient way of tracking compliance using a combination of subjective and objective measures. Each item had four Likert scores, with a minimum score of 0 and a maximum score of 3. The items are subdivided in to (I) patient behavior-related medication adherence questionnaires (5 items) (II) pill/injection burden due to additional disease related questionnaires (4 items), and (III) the third subsection is payment-related questionnaires (2 items). The GMAS instrument of medication adherence has been used and validated in several studies of different chronic diseases [32–35]. The
English version of the questionnaire is also validated [34] with an internal consistency of the items for its reliability test of Cronbach alpha resulted 0.84 and the item-level content validity indexes were ≥ 0.79.

The final outcome score used to categorize the medication adherence level as low adherence and high adherence was determined by computing the sum of each item scores. If the overall GMAS score ≤ 26, the patient was categorized under low adherence and patients were categorized under high adherence if the GMAS score was greater than or equal to 27 out of 33 overall maximum points [36].

**Glycemic control measurement**

In this study, the level of glycemic control is measured based on ADA recommendations. Glycemic level in the range of FBG < 70 mg/dl and > 130 mg/dl to be poor glycemic and FBG of 70–130 mg/dl was good glycemic control. The level of FBG used to determine glycemic control was taken from the average of three recorded FBG’s which were measured for at least a month apart.

**Data quality control and statistical analysis**

Before the actual data collection, the questionnaire was pre-tested on 5% of the study subjects in one of the study areas (excluded from the final analyses) to ensure completeness and consistency of the data collection tool. Then, an appropriate amendment was employed. The data was collected by experienced nurses and pharmacists after getting training for two days. The supervisor explicitly clarified the purpose of the study and about data collection tools and techniques. The data collection procedure was monitored closely. After the medical record identification numbers were entered into the Microsoft excel 2013 and checked for repetition, the patients were interviewed and simultaneously the data was extracted.

Once the data was collected; quality, completeness, consistency and clarity were checked before any further analysis was performed. Then, it was entered into Epi-Info version 8, and transported and analyzed with the Statistical Packages for Social Sciences (SPSS) version-26. Shapiro-Wilk tests, Q-Q plots, and histograms were used to examine the normal distribution of the data. Categorical variables are presented as frequencies and percentages. While means with standard divisions (±SD) were used to display results for continuous variables. A logistic regression model was used to assess the association of medication adherence and glycemic control, and with other predictor variables. Variables with p ≤ 0.2 in the bivariate analysis were considered for further analyses in the multivariable analysis to identify predictor variables with medication adherence and glycemic control status. P < 0.05 at 95% CI was statistically significant.

**Ethical considerations**

Initially, the study was ethically approved by the ethical review committee of the University of Gondar with a reference number of Sop/037/2021. Then, permission confirmation was gained from the selected hospitals to proceed with the study. Participants were asked with both written and verbal consent forms, and after the objectives of the study were briefed, consent was accessed to interview them. Confidentiality was kept and sufficiently anonymized and the study was conducted according to the Helsinki legislation.

**Results**

**Socio-demographic and clinical characteristics of the study participants**

Out of 423 approached participants, 403 samples were included in the final study. Greater than half (54.8%) of the participants were males with a mean (±SD) age of 55±10.8 years. In
addition to T2DM, most of the participants were comorbid with hypertension (71.2%) followed by dyslipidemia (42.4%). An average of 2.8 (ranges: 2–6) medical conditions per patient were recorded. The average FBG level of the participants was estimated to be 176.0 mg/dl (Table 1).

Medications used for treating participants
A greater proportion of the participants (32.5%) were treated with a combination of metformin plus insulin, and NPH insulin accounts higher proportion (46.9%) from types of insulin regimens. Enalapril (24.3%) and atorvastatin (35.5%) were also commonly prescribed antihypertensive and lipid-lowering agents, respectively. An average of 4.2 (range: 2–9) medications were prescribed per patient. The average daily dose of insulin, metformin and glibenclamide were 17.2 units (range: 10–40), 1356.8 (range: 500–2000) mg and 13.2 (ranges: 5–20) mg, respectively (Table 2).

Level of medication adherence of the study participants
A higher proportion of the participants who responded to the GMAS measuring items that they were missed their medications either mostly or sometimes. Overall, the current findings showed that medication adherence is significantly lower. More than three-fourths of the participants (76.9%) 95% CI (72.7–81.1) were low adherent to their medications, with an average overall GMAS score of 22.08 (ranges:15–33) out of 33 points (Table 3 and Fig 1).

Determinants of medication adherence
Predictor variables of the level of medication adherence were identified using logistic regression analysis. The multivariable logistic regression model showed that sources of medication cost coverage, monthly income, SMBG practice, number of medications and medical conditions were found to have a significant association with the level of medication adherence. Participants who covered their medication costs out of pocket were found more likely to be low adherent to their medication compared to those who received medications without payment [AOR = 10.593, 95% CI (2.628–41.835); p = 0.003]. Similarly, patients with lower monthly income (< 1500, 1500–2999, and 3000–4999) were also found more likely to have low adherence to their medications compared to patients who had 5000 and higher monthly income [AOR = 13.896, 95% CI (2.598–46.199), AOR = 9.369, 95% CI (2.940–25.785) and AOR = 5.095, 95% CI (2.549–13.308); p < 0.001], respectively. In contrast, patients who could practice SMBG, patients with a lower number of medications (≤ 3) and patients with two medical conditions were found less likely to be low adherent to their medications compared to patients who did not practice SMBG, patients with greater than or equal to six numbers of medications and patients with greater than or equal to five medical conditions: [AOR = 0.266, 95% CI (0.117–0.604); p = 0.002], [AOR = 0.068, 95% CI (0.004–0.813); p = 0.014] and [AOR = 0.307, 95% CI (0.026–0.437); p = 0.018], respectively (Table 4).

Level of glycemic control and its association with medication adherence and other variables
Overall, the average blood glucose level of the participants was far higher than the target level, with an average FBG of 176.0±51.4 mg/dl (ranges: 89–349). Compared to adherent patients (Mn = 130.1) nonadherent participants had significantly worse FBG levels (Mn = 190.9). In terms of the level of glycemic control, around three-fourths (74.7%) of the study participants...
### Table 1. Socio-demographic and clinical characteristics of T2DM patients with comorbidity at hospitals in Northwest Ethiopia from January to March, 2022 (N = 403).

| Socio-demographic variables                        | Frequency (%) | Mean (±SD) |
|---------------------------------------------------|---------------|------------|
| **Sex**                                           |               |            |
| Male                                              | 221 (54.8)    |            |
| Female                                            | 182 (45.2)    |            |
| **Age in years**                                  | -             | 55(±10.8)  |
| **Weight in Kg.**                                 | -             | 65.6(±8.3) |
| **Residence**                                     |               |            |
| Urban                                             | 237 (58.8)    |            |
| Rural                                             | 166 (41.2)    |            |
| **Educational status**                            |               |            |
| Unable to read and write                          | 55 (13.6)     |            |
| Primary school                                    | 133 (33)      |            |
| Secondary school                                  | 150 (37.2)    |            |
| University or college and above                   | 65 (16.1)     |            |
| **Occupation**                                    |               |            |
| Farmer                                            | 74 (18.4)     |            |
| Government employee                               | 103 (25.6)    |            |
| Self-employed                                     | 98 (24.3)     |            |
| Student                                           | 43 (10.7)     |            |
| Unemployed                                        | 63 (15.6)     |            |
| Others                                            | 22 (5.5)      |            |
| **Monthly income (ETH.Birr)**                     |               | 3775.4(±1627.2) |
| **Source of medication cost coverage**            |               |            |
| Health insurance                                  | 233 (57.8)    |            |
| Out of pocket                                     | 122 (30.3)    |            |
| Free                                              | 48 (11.9)     |            |
| **Body mass index (Kg/M²)**                       |               |            |
| Low                                               | 34 (8.4)      | 24.6(±11.2) |
| Normal                                            | 235 (58.3)    |            |
| Over weight                                       | 56 (13.9)     |            |
| Obese                                             | 78 (19.4)     |            |
| **Duration since T2DM diagnosis (years)**         |               |            |
| 1–5                                               | 30 (7.4)      | 13.4(±7.8) |
| 6–10                                              | 141 (35)      |            |
| 11–20                                             | 187 (46.4)    |            |
| > 20                                              | 45 (11.2)     |            |
| **Cigarette Smoking status**                      |               |            |
| Currently smoker                                  | 69 (17.1)     |            |
| Previously smoker                                 | 97 (24.1)     |            |
| Non-smoker at all                                 | 237 (58.8)    |            |
| **Alcohol drinking habit**                        |               |            |
| No                                                | 182 (45.2)    |            |
| Yes                                               | 221 (54.8)    |            |
| **Self-monitoring of blood glucose**              |               |            |
| Yes                                               | 125 (31)      |            |
| No                                                | 278 (69)      |            |
| **Family history of T2DM**                        |               |            |
| Yes                                               | 263 (65.3)    |            |
| No                                                | 140 (34.7)    |            |
| **Physical activity**                             |               |            |
| Sedentary                                         | 181 (44.9)    |            |
| Moderate                                          | 138 (34.2)    |            |
| Vigorous                                          | 84 (20.8)     |            |

(Continued)
had a poor level of glycemic control, and only one-fourth (25.3%) had achieved a target glycemic level.

The multivariable logistic regression model showed that SMBG practice of the patients, level of BMI (Kg/m$^2$) and level of medication adherence were found to have a significant association with the level of glycemic control in patients with T2DM with comorbidity. With holding other variables constant, patients who could practice SMBG [AOR = 0.319, 95% CI (0.056–0.829); p = 0.020], patients who had a normal level of BMI [AOR = 0.280 95% CI (0.002–0.474); p = 0.013], and patients with high medication adherence [AOR = 0.003, 95% CI (0.000–0.113); p = 0.002] were found less likely to have poor glycemic control compared with patients who were not practiced SMBG, patients with obesity and patients who had low medication adherence, respectively (Table 5).

### Discussion

This institutional-based multicenter study has gone through highlighting the level of medication adherence using a structured questionnaire of GMAS for chronic diseases and its impact on glycemic control in T2DM patients with comorbidity. Ensuring medication adherence in patients with chronic conditions, especially in multimorbid patients is continued to be the most challenging in healthcare practice because of medication complexity and its multiple burden. The problem is more severe in low-income countries and poor settings where there is a low level of patients’ educational status, knowledge about diabetes and medications [25–28]. In Ethiopia, a significant proportion of patients with T2DM have comorbid conditions like hypertension, dyslipidemia and macrovascular and microvascular complications [29]. However, medication adherence can be influenced by the medication regimen complexity and the polypharmacy [30, 31, 37] used to treat these comorbidities. Poor glycemic control because of poor medication adherence can increase the risk of negative consequences and medical costs.
with significant impactful problems to the sustainability of the healthcare system [3, 17, 22–24].

The current study showed that a higher proportion of T2DM patients with comorbidity were low adherent to their medications and were found to have a poor level of glycemic control. Participants who covered their medication costs out of pocket and those patients with lower monthly income were found more likely to have low adherence to their medications. However, patients who could practice SMBG, patients with a lower number of medications and those patients with a lower number of medical conditions were found less likely to become low adherent to their medications. Further, this study disclosed that the level of glycemic control was found to have a significant association with the level of medication adherence.

In this study, most of the participants were found to have a low level of medication adherence. This finding is consistent with an earlier study [38], but it is much higher than the other studies [14, 18, 36, 39–41]. The study findings indicate that a significant proportion of patients with comorbidity fail to achieve the expected adherence level of medications. This might be

Table 2. Distribution of medications used to the treatment of T2DM patients with comorbidity.

| Medications                              | Frequency (%) | Mean (±SD) |
|------------------------------------------|---------------|------------|
| **Antidiabetic medications**             |               |            |
| Metformin plus insulin                   | 131 (32.5)    |            |
| Metformin plus glibenclamide             | 76 (18.9)     |            |
| Metformin                                | 74 (18.4)     |            |
| Metformin plus glibenclamide plus insulin| 63 (15.6)     |            |
| Insulin                                  | 59 (14.6)     |            |
| **Types of insulin regimens**            |               |            |
| NPH                                      | 189 (46.9)    |            |
| Premixed insulin                         | 68 (16.9)     |            |
| **Antihypertensive and cardiovascular agents** |         |            |
| Enalapril                                | 98 (24.3)     |            |
| Amlodipine                               | 66 (16.4)     |            |
| Hydrochlorothiazide                      | 56 (13.9)     |            |
| Atenolol                                 | 19 (4.7)      |            |
| Metoprolol                               | 15 (3.7)      |            |
| Nifedipine                               | 12 (3)        |            |
| Furosemide                               | 7 (1.7)       |            |
| **Lipid-lowering agents**                |               |            |
| Atorvastatin                             | 143 (35.5)    |            |
| Simvastatin                              | 48 (11.9)     |            |
| Aspirin (ASA)                            | 67 (16.6)     |            |
| Amitriptyline                            | 23 (5.7)      |            |
| TDF/3TC/DTG                              | 11 (2.7)      |            |
| Warfarin                                 | 6 (1.5)       |            |
| Propyl thiouracil                        | 5 (1.2)       |            |
| Salbutamol plus beclomethasone           | 5 (1.2)       |            |
| Others*                                  | 19 (1.6)      |            |
| **Number of medications**                |               | 4.2 (±1.4) |
| **Average daily dose of insulin (Unit)** |               | 17.2 (±5.9) |
| **Average daily dose of metformin (mg)** |               | 1356.8 (±1428.9) |
| **Average daily dose of glibenclamide (mg)** |             | 13.2 (±5.1) |
| **Average daily dose of Atorvastatin (mg)** |             | 43.2 (±30.8) |
| **Average daily dose of Simvastatin (mg)** |             | 26.1 (±28.1) |

TDF, Tenofovir disoproxil fumarate; 3TC, Lamivudine; DTG, Dolutegravir; others
* include antibiotics, gastrointestinal drugs and antipains.

https://doi.org/10.1371/journal.pone.0274971.t002
Table 3. Medication adherence with respect to GMAS measuring items.

| GMAS measuring item descriptions                                                                 | Adherence response levels n (%) | Mean (±SD) Score |
|-------------------------------------------------------------------------------------------------|---------------------------------|------------------|
| 1. Difficulty in remember to take medications                                                  | 8 (19) 258 (64) 137 (34)        | 2.32 (±0.5)       |
| 2. Forgetting medications due to busy schedules, travel and other events                       | 30 (7.4) 253 (62.8) 120 (29.8)  | 2.22 (±0.6)       |
| 3. Discontinuing medications when feeling well                                                   | 109 (27) 192 (47.6) 102 (25.3) | 1.98 (±0.7)       |
| 4. Stopping taking medications due to adverse effects                                           | 4 (1) 338 (83.9) 61 (15.1)     | 2.14 (±0.4)       |
| 5. Stop medications without telling a doctor                                                    | 49 (12.2) 240 (59.6) 114 (28.3) | 2.16 (±0.6)       |
| 6. Discontinuing medications due to other medicines for additional diseases                    | 1 (0.2) 81 (20.1) 254 (63)     | 1.96 (±0.6)       |
| 7. Find it hassle to remember medications due to medication regimen complexity                  | 2 (0.5) 61 (15.1) 279 (69.2)   | 1.99 (±0.6)       |
| 8. Missing medicines due to progression of disease and addition of new medicines in the last month | 85 (21.1) 245 (60.8) 73 (18.1) | 1.97 (±0.6)       |
| 9. Altering medication regimen, dose and frequency                                              | 123 (30.5) 214 (53.1) 66 (16.4) | 1.86 (±0.7)       |
| 10. Discontinuing medications because they are not worth for the money                          | 1 (0.2) 124 (30.8) 251 (62.3)  | 1.73 (±0.6)       |
| 11. Find it difficult to buy medicines because they are expensive                               | 1 (0.2) 143 (35.5) 226 (56.1)  | 1.72 (±0.6)       |

Overall GMAS mean score 22.08 (4.4)

Note: Always = 0; mostly = 1; sometimes = 2; never = 3.

because patients may discontinue medications due to other medications for additional diseases and or it might be difficult to remember medications due to medication regimen complexity. The current study also disclosed that around two-thirds of the participants responded that they discontinued medications either sometimes or mostly because of other medicines for...
additional problems and difficulty in remembering because of medication complexity. The other possibilities for their lower medication adherence are the patients’ fear of medication adverse effects, medication expensiveness and poor patients’ behavior towards their medication. Thus, the findings have implications, which need to be focused towards improving the medication adherence of T2DM patients with comorbidity. In addition, particularly in Ethiopia, the problem might be related to a low level of patients’ knowledge about the diabetes, their medications and low socio-economic status, literacy status, cultural and personal perceptions as well as healthcare factors. The previous study also showed that personal beliefs and literacy status have a significant association with medication adherence in patients with chronic illness. Therefore, in Ethiopian settings and population, personal beliefs and literacy status could be addressed in the prescription of medications.

This study showed that the source of cost coverage of medications was significantly associated with levels of medication adherence, which patients who were paid out of pocket for their medication were found more likely to have poor medication adherence compared with...
patients who received their medication freely. This finding agrees with previous studies [42–44]. The finding indicates that patients who cover medication costs directly form out of pocket may sustain an increase in medication costs and be forced to withdraw when the medication cost become expensive. In this study, a significant number of participants also responded that

Table 5. Association of medication adherence and other predicted variables with glycemic control in T2DM patients with comorbidity.

| Variables                          | Glycemic control | 95% CI                  | P-value |
|-----------------------------------|------------------|-------------------------|---------|
|                                   | Poor             | Good                    | AOR     |
| Medication cost coverage          |                  |                         |         |
| Health insurance                  | 169              | 64                      | 1.886(0.993–3.584) | 0.231(0.021–2.513) | 0.296 |
| Out of pocket                     | 104              | 18                      | 4.127(1.927–8.836) | 0.694(0.043–11.113) |       |
| Free                              | 28               | 20                      | 1       | 1       |
| Monthly income (ETH.Birr)         |                  |                         |         |
| < 1500                            | 51               | 9                       | 4.617(2.048–10.408) | 1.354(0.114–16.046) | 0.135 |
| 1501–2999                         | 42               | 9                       | 3.802(1.670–8.656) | 1.142(0.135–3.308) |       |
| 3000–4999                         | 154              | 40                      | 3.137(1.849–5.322) | 2.351(0.256–21.616) |       |
| ≥ 5000                            | 54               | 44                      | 1       | 1       |
| SMBG practice                     |                  |                         |         |
| Yes                               | 67               | 58                      | 0.217(0.135–0.350) | 0.319(0.056–0.829) | 0.020' |
| No                                | 234              | 44                      | 1       | 1       |
| BMI (K/m²)                        |                  |                         |         |
| Low                               | 27               | 7                       | 0.380(0.122–1.186) | 0.435(0.014–1.465) | 0.013' |
| Normal                            | 161              | 74                      | 0.215(0.094–0.489) | 0.280(0.002–0.474) |       |
| Overweight                        | 42               | 14                      | 0.296(0.111–0.791) | 0.168(0.005–6.249) |       |
| Obese                             | 71               | 7                       | 1       | 1       |
| Physical activity                 |                  |                         |         |
| Sedentary                         | 140              | 41                      | 0.866(0.459–1.636) | 0.464(0.037–5.891) | 0.823 |
| Moderate                          | 94               | 44                      | 0.542(0.285–1.030) | 0.501(0.046–5.437) |       |
| Vigorous                          | 67               | 17                      | 1       | 1       |
| Hypoglycemia                      |                  |                         |         |
| Yes                               | 29               | 23                      | 0.366(0.201–0.669) | 1.656(0.192–14.310) | 0.647 |
| No                                | 272              | 79                      | 1       | 1       |
| Hypertension                      |                  |                         |         |
| Yes                               | 222              | 65                      | 1.600(0.991–2.581) | 0.978(0.143–6.684) | 0.982 |
| No                                | 79               | 37                      | 1       | 1       |
| Antidiabetic medications          |                  |                         |         |
| Metformin plus glibenclamide plus insulin | 51          | 12                      | 0.974(0.393–2.415) | 2.023(0.147–27.786) | 0.878 |
| Metformin plus insulin            | 90               | 41                      | 0.250(0.237–1.067) | 0.652(0.071–6.009) |       |
| Metformin plus glibenclamide      | 64               | 12                      | 1.222(0.497–3.005) | -           |       |
| Metformin                         | 48               | 26                      | 0.423(0.188–0.952) | -           |       |
| Insulin                           | 48               | 11                      | 1       | 1       |
| Types of insulin regimens         |                  |                         |         |
| NPH                               | 152              | 37                      | 2.876 (1.575–5.250) | 3.249(0.534–19.754) | 0.201 |
| Premixed                          | 40               | 28                      | 1       | 1       |
| Lipid lowering agents             |                  |                         |         |
| Atorvastatin                      | 116              | 27                      | 1.953(0.932–4.094) | 4.249(0.706–25.562) | 0.114 |
| Simvastatin                       | 33               | 15                      | 1       | 1       |
| Number of medications             |                  |                         |         |
| ≤ 3                               | 95               | 54                      | 0.227(0.101–0.510) | 0.076(0.001–4.215) | 0.321 |
| 4–5                               | 144              | 40                      | 0.465(0.206–1.050) | 0.227(0.027–1.911) |       |
| ≥ 6                               | 62               | 8                       | 1       | 1       |
| Number of medical conditions      |                  |                         |         |
| 2                                 | 131              | 62                      | 0.616(0.252–1.507) | 5.309(0.384–79.787) | 0.113 |
| 3                                 | 112              | 27                      | 1.210(0.472–3.100) | 5.858(0.415–82.675) |       |
| 4                                 | 34               | 6                       | 1.653(0.493–5.338) | 1.336(0.134–13.279) |       |
| ≥ 5                               | 24               | 7                       | 1       | 1       |
| Level of medication Adherence     |                  |                         |         |
| High                              | 17               | 76                      | 0.020(0.011–0.040) | 0.003(0.000–0.113) | 0.002' |
| Low                               | 284              | 26                      | 1       | 1       |

AOR: Adjusted odds ratio, COR: crude odds ratio, CI: confidence interval
* indicated p value < 0.05.

https://doi.org/10.1371/journal.pone.0274971.1005
they were discontinued medications because they are not worth for the money and find it difficult to buy medicines because they are expensive. Medication adherence of patients suffers because of high drug costs [45], particularly the problem might be much higher for patients who pay out of pocket. Cost-sharing may deter clinically vulnerable patients from initiating essential medications, compromise adherence and result in treatment failure. Here, patients may benefit from healthcare insurance, which helps them access their medications with optimum pre-paid coverage cost [46, 47]. Therefore, particularly patients with chronic diseases like T2DM may benefit and could be engaged in the Ethiopian health insurance systems with an optimum pre-paid healthcare access coverage cost, which can protect them from catastrophic healthcare expenditures for their medications and treatments. Moreover, this study also showed that patients with low household incomes were found more likely to be low adherent to their medications compared to patients who had relatively high household income. This finding agrees with previous studies [42, 43, 48], which patients with low economic status and household income have the potential to withdraw medications because of affordability issues. This problem is severe in chronic illnesses and patients with comorbidities because of increased medication costs for treating additional conditions. Particularly in Ethiopian settings, most patients are with low socio-economic status [25–28]. In contrary, most patients with T2DM are with comorbid conditions [29]. Thus, this finding indicates that healthcare providers and prescribers could come up with appreciating the socio-economic status of the patients, and clear and good communication towards the affordability of the prescribed medications. The patients may also benefit from the Ethiopian community-based health insurance (CBHI) systems, which may help individuals by providing optimum pre-paid coverage costs and protect them from catastrophic expenditures.

Patients who could practice SMBG were found less likely to have low adherence to their medications compared to patients who did not practice SMBG. This finding implies that patients who practice SMBG can obtain direct feedback on the level of blood glucose and use that information to adjust their choice and help them adhere to their medications. Although the SMBG is an important tool for improving patient self-management and clinicians may use it in guiding medications [49], the current study showed that a significant proportion of patients did not practice SMBG. But the clinical significance of SMBG may depend on the patients understanding of the technical procedures, adherence to the practice, and interpretation of the results. Therefore, patients could be encouraged to practice SMBG, share their testing results with healthcare providers, and the clinicians act towards making treatment decisions [49, 50]. Further, the current study also disclosed that patients with a lower number of medications and medical conditions were found less likely to be low adherent to their medications compared with patients with a higher number of medications and medical conditions. This finding is consistent with previous studies [30, 31, 36, 37], which higher number of medications and medical conditions resulted in low medication adherence because of medication regimen complexity, medication adverse effects, the inability of patients to afford multiple medications. A higher number of medications may also contribute to the loss of the time of administration of medications. Therefore, healthcare providers, in particular prescribers, could focus on practicing with prescribing of optimum number of medications by considering the need of medication treatment of the medical conditions in patients with comorbidity. Patients also need to be highly vigilant and motivated to adhere to their multiple medications, which are necessary to treat the possible and presented comorbidities.

The current study also examined the association of medication adherence and level of glycemic control. In line with previous studies [28, 29, 51–54], majority of patients were under poor glycemic control. Consistent with the previous studies [14, 28, 39, 55], patients who had a low level of medication adherence were found more likely to have poor glycemic control. The
findings may imply that poor glycemic control in the majority of Ethiopian population and settings might be related to low medication adherence. But medication adherence of patients could maximize the effectiveness of pharmaceutical therapy. Thus, patients could be recommended to adhere to their medications. Additionally, patients who could practice SMBG were found less likely to have poor glycemic control compared to patients who didn’t practice SMBG. This finding is consistent with previous studies [56–58], which indicate that SMBG can be important in adjusting the level of glycemic control by adhering to medications and taking appropriate measures to improve poor glycemic levels when there are higher blood glucose levels. This finding implies that patients could be recommended to practice SMBG. They also use the SMBG data to adjust their practice, medication adherence and communicate with their healthcare providers and use the data to act on treatment decisions. Moreover, in consistent with previous studies [59–61], patients who had normal BMI were found less likely to have poor glycemic control compared with obese patients. This relation might justify those patients with higher BMI or obesity caused to insulin resistance and in turn, obesity may result in poor glycemic control in the long term. Thus, patients with diabetes could be recommended to reduce their overweight to a normal level by different recommended daily physical activities and modification of diets. In Ethiopia, unhealth sedentary lifestyle has increased and it is among the risk factors of diabetes. Therefore, patients with T2DM could be engaged with an optimum daily physical activity and adjust their diets, and lifestyles.

Generally, this study highlighted the extent of medication adherence and its impact on glycemic control among T2DM patients with comorbidity in resource-limited settings. The findings also have an implication to take measures in the management of T2DM patients with comorbidities. It has explored the medication adherence by assessing patient-behaviors towards their medication adherence, pill/injection burdens due to other medications, and payment related factors to adhere to medications, this tries addressing potential contributors to poor medication adherence in the Ethiopian settings and populations. Indeed, the rapid rise in the prevalence and burden of diabetes mellitus in developing countries, particularly in Ethiopia, where most of the diabetes patients are with comorbid illness and low awareness of the patients towards the disease and medications could seek an urgent intervention towards ensuring medication adherence and achieving glycemic targets. The study may add some background knowledge of the practitioners and patients, and help them towards treatment decisions and modifications accordingly.

The current study has some limitations. The adherence level is determined through patients’ self-reported adherence measuring scale, which depends on the honesty and faith in the respondents and could affect the responses resulting in an over or underestimation of the adherence level of medications. Despite this limitation, we hope this study will fill the existing literature gap in the study area and add a body of knowledge to the management practice of T2DM patients with comorbidities.

Conclusion

The current study concluded that medication adherence was low and significantly associated with glycemic control of patients. Medication cost coverage, monthly income, SMBG practice, number of medications and medical conditions were found to have significant association with medication adherence. On the other hand, glycemic control was found to have a significant association with SMBG practice, level of BMI and level of medication adherence. Therefore, management interventions of T2DM patients with comorbidity should focus on improving medication adherence and other predictor variables.
Supporting information

S1 Dataset. Dataset: A data set used to analyze and generate the data. (SAV)

Acknowledgments

The authors want to thank the University of Gondar for providing ethical approval to the study and the selected hospitals for their positive cooperation during the study. We would also like to forward our gratitude to the data collectors and study participants.

Author Contributions

Conceptualization: Ashenafi Kibret Sendekie.

Data curation: Ashenafi Kibret Sendekie, Adeladlew Kassie Netere, Asmamaw Emagn Kasahun, Eyayaw Ashete Belachew.

Formal analysis: Ashenafi Kibret Sendekie, Adeladlew Kassie Netere, Asmamaw Emagn Kasahun, Eyayaw Ashete Belachew.

Investigation: Ashenafi Kibret Sendekie, Eyayaw Ashete Belachew.

Methodology: Ashenafi Kibret Sendekie, Adeladlew Kassie Netere, Asmamaw Emagn Kasahun, Eyayaw Ashete Belachew.

Project administration: Ashenafi Kibret Sendekie.

Resources: Ashenafi Kibret Sendekie.

Software: Ashenafi Kibret Sendekie.

Supervision: Adeladlew Kassie Netere, Asmamaw Emagn Kasahun, Eyayaw Ashete Belachew.

Validation: Adeladlew Kassie Netere, Asmamaw Emagn Kasahun, Eyayaw Ashete Belachew.

Writing – original draft: Ashenafi Kibret Sendekie.

Writing – review & editing: Ashenafi Kibret Sendekie, Adeladlew Kassie Netere, Asmamaw Emagn Kasahun, Eyayaw Ashete Belachew.

References

1. Sun H, Saedi P, Karuranga S, Pinkepank M, Ogurtsova K, Duncan BB, et al. IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res Clin Pract. 2022; 183:109119. https://doi.org/10.1016/j.diabres.2021.109119 PMID: 34879977

2. Organization WH. Newsroom Fact sheets and details about diabetes: Fact sheet. Diabetes Programme. WHO, Geneva, 2021. Available from: https://www.who.int/news-room/fact-sheets/detail/diabetes/ (accessed: 20 May 2022).

3. Ogurtsova K, da Rocha Fernandes JD, Huang Y, Linnenkamp U, Guariguata L, Cho NH, et al. IDF Diabetes Atlas: Global estimates for the prevalence of diabetes for 2015 and 2040. Diabetes Research and Clinical Practice. 2017; 128:40–50. https://doi.org/10.1016/j.diabres.2017.03.024 PMID: 28437734

4. International Diabetes Federation, IDF diabetes atlas. Eighth edition. ed. 2017, [Brussels]: International Diabetes Federation. 147 pages: illustrations, tables, figures; 30 cm.

5. Bishu KG, Jenkins C, Yebyo HG, Atsbha M, Wubayehu T, Gebregziabher M. Diabetes in Ethiopia: A systematic review of prevalence, risk factors, complications, and cost. Obesity Medicine. 2019.

6. Zeru MA, Tesfa E, Mitiku AA, Seyoum A, Bokoro TA. Prevalence and risk factors of type-2 diabetes mellitus in Ethiopia: systematic review and meta-analysis. Sci Rep. 2021; 11(1):21733. https://doi.org/10.1038/s41598-021-01256-9 PMID: 34741064
7. Anifull M, John LJ, Sreedharan J, Mutappallymyail J, Basha SA. Patients’ Adherence to Anti-Diabetic Medications in a Hospital at Ajman, UAE. The Malaysian journal of medical sciences: MJMS. 2014; 21(1):44–9.

8. Darkwa S, editor Prevalence of diabetes mellitus and resources available for its management in the Cape Coast Metropolis 2011.

9. Sharma T, Kaifa J, Dhasmana D, Basera H. Poor adherence to treatment: A major challenge in diabetes. Journal, Indian Academy of Clinical Medicine. 2014; 15.

10. Fischer MA, Stedman MR, Li J, Vogeli C, Shrank WH, Brookhart MA, et al. Primary medication non-adherence: analysis of 195,930 electronic prescriptions. Journal of general internal medicine. 2010; 25(4):284–90. https://doi.org/10.1007/s11606-010-1253-9 PMID: 20131023

11. Ho PM, Rumsfeld JS, Masoudi FA, McClure DL, Plomondon ME, Steiner JF, et al. Effect of medication nonadherence on hospitalization and mortality among patients with diabetes mellitus. Archives of internal medicine. 2006; 166(17):1836–41. https://doi.org/10.1001/archinte.166.17.1836 PMID: 17000939

12. De Geest S, Sabaté E. Adherence to Long-Term Therapies: Evidence for Action. European Journal of Cardiovascular Nursing. 2003; 2(4):323. https://doi.org/10.1016/S1474-5151(03)00091-4 PMID: 14667488

13. Belachew EA, Netere AK. Sendekie AK. Adherence to Inhaled Corticosteroid Therapy and Its Clinical Impact on Asthma Control in Adults Living with Asthma in Northwestern Ethiopian Hospitals. Patient Prefer Adherence. 2022; 16:1321–32. https://doi.org/10.2147/PPA.S365222 PMID: 35642244

14. Lin L-K, Sun Y, Heng BH, Chew DEK, Chong P-N. Medication adherence and glycemic control among newly diagnosed diabetes patients. BMJ Open Diabetes Research & Care. 2017; 5(1):e000429. https://doi.org/10.1136/bmjdr-2017-000429 PMID: 2887894

15. Dragomir A, Côté R, Roy L, Blais L, Lalonde L, Bérard A, et al. Impact of adherence to antihypertensive agents on clinical outcomes and hospitalization costs. Medical care. 2010; 48(5):418–25. https://doi.org/10.1097/MLR.0b013e3181d567bd PMID: 20393367

16. Bezie Y, Molina M, Hernandez N, Batista R, Niang S, Huet D. Therapeutic compliance: a prospective analysis of various factors involved in the adherence rate in type 2 diabetes. Diabetes & metabolism. 2006; 32(6):611–6. https://doi.org/10.1016/S1262-3636(07)70316-6 PMID: 17296515

17. Sokol MC, McGuigan KA, Verbrugge RR, Epstein RS. Impact of medication adherence on hospitalization risk and healthcare cost. Medical care. 2005; 43(6):521–30. https://doi.org/10.1097/01.mlr.0000163641.86870.af PMID: 15908846

18. Ayele BA, Tiruneh SA, Ayele AA, Engidaw MT, Yitbarek GY, Gebremariam AD. Medication adherence and its associated factors among type 2 diabetic patients in Ethiopia. BMJ Open Diabetes Research & Care. 2017; 5(1):e000429.

19. Plakas Storitios, Mastrogiannis Dimos, Mantzorou Marianna, Adamakidou Theodoula, Fouka Georgia, Bouziou Angeliki, et al. Validation of the 8-Item Morisky Medication Adherence Scale in Chronically Ill Ambulatory Patients in Rural Greece. Open J Nurs 2016; 6(03): 158.

20. Bruce SP, Acheampong F, Kretchy I. Adherence to oral anti-diabetic drugs among patients attending a Ghanaian teaching hospital. Pharmacy practice. 2015; 13(1):533. https://doi.org/10.18549/pharmpract.2015.01.533 PMID: 25883693

21. Amaltinga APM. Non adherence to diabetic medication among diabetic patients, a case study of Dormaa Hospital Ghana. Science Journal of Public Health 2017; 5(2): 88–97.

22. Fukuda H, Mizobe M. Impact of nonadherence on complication risks and healthcare costs in patients newly-diagnosed with diabetes. Diabetes Research and Clinical Practice. 2017; 123:55–62. https://doi.org/10.1016/j.diabres.2016.11.007 PMID: 27940390

23. Hong J.S. and Kang H.C. Relationship Between Oral Antihyperglycemic Medication Adherence and Hospitalization, Mortality, and Healthcare Costs in Adult Ambulatory Care Patients With Type 2 Diabetes in South Korea. Medical Care, 2011. 49(4).

24. Breitscheidel L, Stamenitis S, Dippel FW, Schöffski O. Economic impact of compliance to treatment with antidiabetic medication in type 2 diabetes mellitus: a review paper. Journal of Medical Economics. 2010; 13(1):8–15. https://doi.org/10.3111/13696990093479199 PMID: 19947905

25. Mesfin Y, Assegid S, Beshir M. Medication adherence among type 2 diabetes ambulatory patients in Zewdu Memorial Hospital, Addis Ababa, Ethiopia. Epidemiology (Sunnyvale). 2017; 7(5):1–12.

26. Abebaw M, Messele A, Hallu M, Zewdu F. Adherence and associated factors towards anti-diabetic medication among type II diabetic patients on follow-up at University of Gondar Hospital, Northwest Ethiopia. Advances in nursing. 2016; 2016.

27. El-Hadiyah TM, Madani AM, Abdelrahim HM, Youaif AK. Factors affecting medication non adherence in type 2 Sudanese diabetic patients. Pharmacology & Pharmacy. 2016; 7(4):141–6.
28. Kassahun T, Eshetie T, Gesessew H. Factors associated with glycemic control among adult patients with type 2 diabetes mellitus: a cross-sectional survey in Ethiopia. BMC Research Notes. 2016; 9(1):78. https://doi.org/10.1186/s13104-016-1896-7 PMID: 26861243

29. Sendekie AK, Teshale AB, Tefera YG. Glycemic control in newly insulin-initiated patients with type 2 diabetes mellitus: A retrospective follow-up study at a university hospital in Ethiopia. PLOS ONE. 2022; 17(5):e0268639. https://doi.org/10.1371/journal.pone.0268639 PMID: 35617250

30. Ayele AA, Tegegn HG, Ayele TA, Ayalew MB. Medication regimen complexity and its impact on medication adherence and glycemic control among patients with type 2 diabetes mellitus in an Ethiopian general hospital. BMJ Open Diabetes Research & Care. 2019; 7(1):e000685.

31. de Vries ST, Keers JC, Visser R, de Zeeuw D, Haaijer-Ruskamp FM, Voorham J, et al. Medication adherence, treatment complexity, and non-adherence to different drug classes in patients with type 2 diabetes. Journal of psychosomatic research. 2014; 76(2):134–8. https://doi.org/10.1016/j.jpsychres.2013.11.003 PMID: 24439689

32. Wang Y, Wang X, Wang X, Naqvi AA, Zhang Q, Zang X. Translation and validation of the Chinese version of the general medication adherence scale (GMAS) in patients with chronic illness. Current medical research and opinion. 2021; 37(5):829–37. https://doi.org/10.1080/03007995.2021.1901680 PMID: 33719815

33. Kwan YH, Weng SD, Loh DHF, Phang JK, Oo LJJ, Blalock DV, et al. Measurement properties of existing patient-reported outcome measures on medication adherence: systematic review. Journal of medical internet research. 2020; 22(10):e19179. https://doi.org/10.2196/19179 PMID: 33034966

34. Naqvi AA, Hassali MA, Jahangir A, Nadir MN, Kachela B. Translation and validation of the English version of the general medication adherence scale (GMAS) in patients with chronic illnesses. Journal of drug assessment. 2019; 8(1):36–42. https://doi.org/10.1080/21556660.2019.1579729 PMID: 30863660

35. Naqvi AA, Hassali MA, Rizvi M, Zehra A, Iffat W, Haseeb A, et al. Development and validation of a novel General Medication Adherence Scale (GMAS) for chronic illness patients in Pakistan. Frontiers in pharmacology. 2018; 9:1124. https://doi.org/10.3389/fphar.2018.01124 PMID: 30356775

36. Allaham KK, Feyasa MB, Govender RD, Musa AMA, AlKaabi AJ, ElBarazi I, et al. Medication Adherence Among Patients With Multimorbidity in the United Arab Emirates. Patient Prefer Adherence. 2022; 16:1187. https://doi.org/10.2147/PPA.S355891 PMID: 35572810

37. Ab Rahman N, Lim MT, Thevendaran S, Ahmad Hamdi N, Sivasampu S. Medication Regimen Complexity and Medication Burden Among Patients With Type 2 Diabetes Mellitus: A Retrospective Analysis. Front Pharmacol. 2022; 13:808190. https://doi.org/10.3389/fphar.2022.808190 PMID: 35387353

38. Foley L, Larkin J, Lombard-Vance R, Murphy AW, Hynes L, Galvin E, et al. Prevalence and predictors of medication non-adherence among people living with multimorbidity: a systematic review and meta-analysis. BMJ Open. 2021; 11(9):e044987. https://doi.org/10.1136/bmjopen-2020-044987 PMID: 34475141

39. Osei-Yeboah J, Lokpo SY, Owiredu WK, Johnson BB, Orish VN, Botchway F, et al. Medication Adherence and Its Association with Glycaemic Control, Blood Pressure Control, Glycosuria and Proteinuria Among People Living With PLWD in the Ho Municipality, Ghana. The Open Public Health Journal. 2018; 11(1).

40. Walsh CA, Bennett KE, Wallace E, Cahir C. Identifying Adherence Patterns Across Multiple Medications and Their Association With Health Outcomes in Older Community-Dwelling Adults With Multimorbidity. Value in Health. 2020; 23(8):1063–71. https://doi.org/10.1016/j.jval.2020.03.016 PMID: 32828219

41. Afaya RA, Bam V, Azongo TB, Afaya A, Kusi-Amponsah A, Ajusiyi JM, et al. Medication adherence and self-care behaviours among patients with type 2 diabetes mellitus in Ghana. PLOS ONE. 2020; 15(8):e0237710. https://doi.org/10.1371/journal.pone.0237710 PMID: 32822381

42. Morgan SG, Lee A. Cost-related non-adherence to prescribed medicines among older adults: a cross-sectional analysis of a survey in 11 developed countries. BMJ Open. 2017; 7(1):e014287. https://doi.org/10.1136/bmjopen-2016-014287 PMID: 28143838

43. Taha MB, Valero-Elizondo J, Yahya T, Caraballo C. Cost-Related Medication Nonadherence in Adults With Diabetes in the United States: The National Health Interview Survey 2013–2018. 2022; 45(3):594–603.

44. Karter AJ, Parker MM, Solomon MD, Lyles CR, Adams AS, Moffet HH, et al. Effect of Out-of-Pocket Cost on Medication Initiation, Adherence, and Persistence among Patients With Type 2 Diabetes: The Diabetes Study of Northern California (DISTANCE). Health Services Research. 2018; 53(2):1227–47.

45. Abell A. Medication adherence suffers because of high drug costs. Pharmacy Today. 2020; 26(4):29–30.
46. Haile M, Ololo S, Megersa B. Willingness to join community-based health insurance among rural households of Debub Bench District, Bench Maji Zone, Southwest Ethiopia. BMC Public Health. 2014; 14(1):591. https://doi.org/10.1186/1471-2458-14-591 PMID: 24920538
47. Wang H, Ramana GNV. Universal Health Coverage for Inclusive and Sustainable Development: Country Summary Report for Ethiopia. World Bank, Washington, DC. © World Bank. 2014.
48. Kim NH, Look KA, Dague L, Winn AN. Financial burden and medication adherence among near-poor older adults in a pharmaceutical assistance program. Research in Social and Administrative Pharmacy. 2022; 18(3):2517–23. https://doi.org/10.1016/j.sapharm.2021.04.016 PMID: 34030976
49. American Diabetes Association. Diabetes technology: standards of medical care in diabetes-2019. Diabetes care. 2019; 42(Suppl 1):S71–S80.
50. Polonsky WH, Fisher L, Schikman CH, Jelsovsky Z, et al. Structured self-monitoring of blood glucose significantly reduces A1C levels in poorly controlled, noninsulin-treated type 2 diabetes: results from the Structured Testing Program study. Diabetes care. 2011; 34(2):262–7. https://doi.org/10.2337/dc10-1732 PMID: 21270183
51. Yirmam M, Desse TA, Hebo HJ. Glycemic control among ambulatory type 2 diabetes patients with hypertension comorbidity in a developing country: A cross sectional study. Heliyon. 2020; 6(12): e05671. https://doi.org/10.1016/j.heliyon.2020.e05671 PMID: 33319113
52. Gebermariam AD, Tiruneh SA, Ayele AA, Engidaw M. Level of glycemic control and its associated factors among type II diabetic patients in debre tabor general hospital, north west Ethiopia. Metabolism Open. 2020; 8:100056. https://doi.org/10.1016/j.metop.2020.100056 PMID: 32984805
53. Blonde L, Meneghini L, Peng XV, Boss A, Rhee K, Shaunik A, et al. Probability of achieving glycemic control with basal insulin in patients with type 2 diabetes in real-world practice in the USA. Diabetes Therapy. 2018; 9(3):1347–58. https://doi.org/10.1007/s19322-018-0413-5 PMID: 29600507
54. Mata-Cases M, Mauricio D, Franch-Nadal J. Clinical characteristics of type 2 diabetic patients on basal insulin therapy with adequate fasting glucose control who do not achieve HbA1c targets. Journal of diabetes. 2017; 9(1):34–44. https://doi.org/10.1111/1753-0407.12373 PMID: 26749415
55. Ibrahim AO, Agboola SM, Elegbede OT, Ismail WO, Agbesanwa TA, Omolayo TA. Glycemic control and its association with sociodemographics, comorbid conditions, and medication adherence among patients with type 2 diabetes in southwestern Nigeria. Journal of International Medical Research. 2021; 49(10):0300605211044040.
56. Mannucci E, Antenore A, Giorgino F, Scavini M. Effects of structured versus unstructured self-monitoring of blood glucose on glycemic control in patients with non-insulin-treated type 2 diabetes: a meta-analysis of randomized controlled trials. Journal of diabetes science and technology. 2018; 12(1):183–9. https://doi.org/10.1177/19322968171719290 PMID: 28697625
57. Zhu H, Zhu Y, Leung S-W. Is self-monitoring of blood glucose effective in improving glycemic control in type 2 diabetes without insulin treatment: a meta-analysis of randomised controlled trials. Journal of diabetes science and technology. 2018; 12(1):183–9. https://doi.org/10.1177/19322968171719290 PMID: 28697625
58. Gomes T, Juurlink DN, Shah BR, Paterson JM, Mamdani MM. Blood glucose test strips: options to reduce usage. CMAJ. 2010; 182(1):35–8. https://doi.org/10.1503/cmaj.091017 PMID: 20026624
59. Demoz GT, Gebremariam A, Ylfter H, Alebachew M, Niraiyowo YL, Gebreslassie G, et al. Predictors of poor glycemic control among patients with type 2 diabetes on follow-up care at a tertiary healthcare setting in Ethiopia. BMC Research Notes. 2019; 12(1):207. https://doi.org/10.1186/s13104-019-4248-6 PMID: 30947749
60. Chan WB, Chan JCN, Chow CC, Yeung VTF, So WY, Li JKY, et al. Glycaemic control in type 2 diabetes: the impact of body weight, β-cell function and patient education. QJM: An International Journal of Medicine. 2000; 93(3):183–90.
61. Wagai GA, Romshoo GJ. Adiposity contributes to poor glycemic control in people with diabetes mellitus, a randomized case study, in South Kashmir, India. J Family Med Prim Care. 2020; 9(9):4623–6. https://doi.org/10.4103/fjmpc.fjmpc_1148_19 PMID: 33209773